CoronaryAtlas logo
CoronaryAtlas
Hypoxanthine
Pathway / Myocardial injury (shared endpoint)

Hypoxanthine

metabolite

Hypoxanthine is an early metabolite marker of myocardial ischemic injury from accelerated purine degradation.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencehigh
RationalePurine catabolite released during cardiomyocyte ischemic stress and ATP depletion.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
38
C — non-Type-I
79
A — assay feasibility
42
E — evidence strength
32
T1DI (composite)
4
Specificity differential (R−C)-41.1
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(1)